Gardar Sigurdsson, MD
Cardiovascular Disease · Des Moines, IANPI 1043310881
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 57.0% of the total. Reporting peaked in 2023 at $1,490 and has fallen 98.1% since, to $28 in 2025.
Across 54 payments — averaging $46.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$177
- Amgen$176
- Novartis$111
- Cleerly, Inc.$89
- Johnson & Johnson$77
- plus $441 from 15 others
What the payments were for
- Travel & lodging$1,05042%
- Food & beverage$1,41757%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 7 | $1,418 |
| E.r. Squibb & Sons, L.L.C. | 6 | $177 |
| Amgen | 4 | $176 |
| Novartis | 6 | $111 |
| Cleerly, Inc. | 1 | $89 |
| Johnson & Johnson | 5 | $77 |
| AstraZeneca | 5 | $73 |
| Bayer | 2 | $52 |
| Merck | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $35 |
| Boehringer Ingelheim | 2 | $28 |
| GE HealthCare | 1 | $28 |
| Angiodynamics, Inc. | 1 | $28 |
| Itamar Medical Inc | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Pfizer | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NAEOTOM Alpha$1,214
- SOMATOM Force$1,214
- Repatha$125
- CAMZYOS$124
How this compares
$2,490 in reported general payments places this provider in the 70th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 111 | $82,746 |
| FarxigaDapagliflozin Propanediol | 14 | $7,541 |
| XareltoRivaroxaban | 14 | $7,423 |
| Metoprolol Succinate | 183 | $1,895 |
| Rosuvastatin Calcium | 122 | $1,592 |
| Dilt-XrDiltiazem Hcl | 12 | $628 |
| Bumetanide | 22 | $552 |
| Losartan Potassium | 56 | $433 |
| Atorvastatin Calcium | 76 | $422 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 35 | $342 |
| Isosorbide Dinitrate | 11 | $319 |
| Furosemide | 84 | $282 |
| Spironolactone | 92 | $271 |
| Potassium Chloride | 14 | $240 |
| Lisinopril | 45 | $214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $82,746111 claims |
| AstraZenecaFarxiga | $73 | $7,54114 claims |
| Johnson & JohnsonXarelto | $77 | $7,42314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Des Moines
- Craig StarkDes Moines$28K
- Shubha Deep RoyDes Moines$9K
- Nelson Telles GarciaDes Moines$7K
- Wafic ItaniDes Moines$5K
- Marc KleinDes Moines$5K
- Eduardo AntezanoDes Moines$4K
- Muhammad AwanDes Moines$4K
- Ratna GangiDes Moines$2K
- Deepika AbbadiDes Moines$2K
- Abdul ChughtaiDes Moines$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.